Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Clinical Trials

European Commission

More Like This

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

PR Newswire associated0

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

PR Newswire associated0

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer